Back to search results

Comparing Nurtec ODT and Maxalt MLT-ODT for Migraine in the Emergency Department

This study is comparing two medications, Nurtec ODT (rimegepant) and Maxalt MLT-ODT (rizatriptan benzoate), for treating acute migraine headaches in adults who come to the emergency department. Researchers want to see which medication is better at reducing pain within 60 minutes. You might be able to join if you are an adult between 18 and 65 years old, have an acute headache with a pain score of 5 or higher, and are able to understand the study information. The study is currently unclear about its recruitment status.

Study design
This is a randomized, double-blind study comparing Nurtec ODT to Maxalt MLT-ODT. It plans to enroll 80 adult patients.
What's involved
You would receive one of the study medications and have your pain score measured at 60 minutes and 120 minutes.
Compensation
Not stated in the trial record.
Follow-up
Your pain score will be measured at 60 minutes and 120 minutes after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06473597

A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache

Recruiting
PHASE4Ages 18–65InterventionalTreatment
Antonios Likourezos
~80 participants
Updated 2025-10-01 on ClinicalTrials.gov
What's tested:RimegepantRizatriptan Benzoate

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Pain Score at 60 minutes
Measured over 60 minutes

Conditions

Migraine

Explore related trials

Migraine

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Sergey Motov, MD · PRINCIPAL_INVESTIGATOR · Maimonides Medical Center

Who to contact

Sergey Motov, MD
[email protected]
718-283-6000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult ED patients age 18 to 65 years old
Acute headache
Initial Pain score of 5 on a standard 11- point (score 0 to 10) numeric rating scale
Patients will have to be awake, alert, and oriented to person, place, and time
Patients able to demonstrate understanding of the informed consent process and content.
Patients also will have to demonstrate ability to verbalize the nature of any adverse effects they might experience as well as to express their pain severity by using the NRS.

Exclusion

Allergy to Rimegepant or Rizatriptan
Pregnancy and breastfeeding
Unstable vital signs
Inability to provide consent
Suspicion for disease process other than migraine (those requiring emergent brain imaging, with a temperature of 100.4 °F, with objective neurologic findings, secondary headache (an "organic" headache))
Ischemic coronary artery disease (angina pectoris, history of myocardial infarction), coronary artery vasospasm (including Prinzmetal's angina)
History of stroke or transient ischemic attack
Peripheral vascular disease
Ischemic bowel disease,
Uncontrolled hypertension
Use of another 5-HT1 agonist, ergotamine-containing medications, or ergot-type medications (methylsergide)
Hemiplegic or basilar migraine
Concurrent administration or recent discontinuation (within 2 weeks) of a MAO-A inhibitors
Current use of Rimegepant as a prophylactic
Severe Nausea and Vomiting
Severe headache requiring immediate intervention
Severe hepatic impairment
If taking any of the following medications (contraindications):
Monoaminoxidaze (MAO) inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine)
SSRI- Citalopram, Escitalopram, Sertraline
Triptans: Sumatriptan, Zolmitriptan, Imigran
Almotriptan.
Cabergoline.
Dihydroergotamine.
Dihydroergotamine intranasal
Eletriptan
Ergoloid mesylates
Ergotamine
Frovatriptan
Duloxetine
Cyclobenzaprine
Fluoxetine, velafaxine
Trazodone
Tramadol
TCA: nortriptyline (Pamelor), amitriptyline, protriptyline
Amphetamines: methamphetamine (Desoxyn), dextroamphetamine (Adderall, Adderall XR), dextroamphetamine (Dexedrine)
azole antifungals ( ketoconazole, itraconazole)
macrolide antibiotics (clarithromycin, erythromycin)
rifamycins (such as rifampin, rifabutin)
carbamazepine, phenytoin
Cardiac Drug: amiodarone (Nexterone, Pacerone), quinidine, ranolazine (Aspruzyo Sprinkle), verapamil (Verelan, Verelan PM)

What this trial measures

  • Change in Pain Score at 60 minutes60 minutes

    Change in Pain Score between baseline and 60 minutes. Pain score will be measured via validated an 11 point Likert Scale where 0 is no pain, 5 moderate pain and 10 very severe pain.